AU2020229874A1 - Gene therapy for addiction disorders - Google Patents

Gene therapy for addiction disorders Download PDF

Info

Publication number
AU2020229874A1
AU2020229874A1 AU2020229874A AU2020229874A AU2020229874A1 AU 2020229874 A1 AU2020229874 A1 AU 2020229874A1 AU 2020229874 A AU2020229874 A AU 2020229874A AU 2020229874 A AU2020229874 A AU 2020229874A AU 2020229874 A1 AU2020229874 A1 AU 2020229874A1
Authority
AU
Australia
Prior art keywords
rvv
nucleic acid
condition
vector
route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020229874A
Other languages
English (en)
Inventor
Warren C. Lau
Brad Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathways Neuro Pharma Inc
Original Assignee
Pathways Neuro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathways Neuro Pharma Inc filed Critical Pathways Neuro Pharma Inc
Publication of AU2020229874A1 publication Critical patent/AU2020229874A1/en
Priority to AU2025248711A priority Critical patent/AU2025248711A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020229874A 2019-02-27 2020-02-27 Gene therapy for addiction disorders Abandoned AU2020229874A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025248711A AU2025248711A1 (en) 2019-02-27 2025-10-09 Gene Therapy For Addiction Disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811339P 2019-02-27 2019-02-27
US62/811,339 2019-02-27
PCT/US2020/020216 WO2020176796A1 (en) 2019-02-27 2020-02-27 Gene therapy for addiction disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025248711A Division AU2025248711A1 (en) 2019-02-27 2025-10-09 Gene Therapy For Addiction Disorders

Publications (1)

Publication Number Publication Date
AU2020229874A1 true AU2020229874A1 (en) 2021-09-23

Family

ID=72239690

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020229874A Abandoned AU2020229874A1 (en) 2019-02-27 2020-02-27 Gene therapy for addiction disorders
AU2025248711A Pending AU2025248711A1 (en) 2019-02-27 2025-10-09 Gene Therapy For Addiction Disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025248711A Pending AU2025248711A1 (en) 2019-02-27 2025-10-09 Gene Therapy For Addiction Disorders

Country Status (5)

Country Link
US (1) US20220152222A1 (https=)
EP (1) EP3931214A4 (https=)
JP (1) JP2022522004A (https=)
AU (2) AU2020229874A1 (https=)
WO (1) WO2020176796A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850427B2 (en) * 2019-12-02 2023-12-26 West Virginia University Board of Governors on behalf of West Virginia University Methods and systems of improving and monitoring addiction using cue reactivity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146898A1 (en) * 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
GB201404470D0 (en) * 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
EP3931214A1 (en) 2022-01-05
US20220152222A1 (en) 2022-05-19
EP3931214A4 (en) 2023-09-13
JP2022522004A (ja) 2022-04-13
AU2025248711A1 (en) 2025-11-13
WO2020176796A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
US11759506B2 (en) AADC polynucleotides for the treatment of Parkinson's disease
EP1299126B1 (en) Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
AU2001268080A1 (en) Glutamic acid decarboxylase (gad) based delivery systems
JP2018509164A (ja) 組換えＧｌｕｔ１アデノ随伴ウイルスベクターコンストラクトおよびＧｌｕｔ１発現を回復させる方法
US20210198691A1 (en) Compositions and methods for the treatment of parkinson's disease
AU2025248711A1 (en) Gene Therapy For Addiction Disorders
Ciron et al. Human α-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution
JP2021520811A (ja) ヘキソサミニダーゼアルファおよびベータサブユニットをコードしているバイシストロニックａａｖベクターならびにその使用
EP3390623B1 (en) Wilson's disease gene therapy
JP2008523093A (ja) 哺乳類の中枢神経系における導入遺伝子の調節発現
US20060073119A1 (en) Methods for treating neurodegenerative disorders
JP2021522791A (ja) Ａａｖ適合性ラミニン−リンカー重合タンパク質
US20250325703A1 (en) Composition for delivering gene to brain tissue and use thereof
US20220280657A1 (en) Genetic Construct
JP2023512688A (ja) 脊髄損傷後の機能回復を促進するためのマイクロｒｎａ－７組成物およびその使用方法
WO2021046169A1 (en) Methods and compositions for the treatment of als
CN119971081B (zh) 用于治疗智力障碍的组合物、其应用以及药物筛选方法
KR102844372B1 (ko) 뇌 성상교세포 특이적 유전자 전달이 가능한 아데노부속바이러스 변이체와 이의 응용
KR20240017311A (ko) Aav 전달을 위한 조성물 및 aav 전달 효율 스크리닝 방법
AU2004101085A4 (en) Glutamic acid decarboxylase (GAD)based delivery systems
WO2025038955A9 (en) Systems and methods for improving safety of split intein aav mediated gene therapy
WO2023201350A2 (en) A gene-based approach to confer long-lasting protection from opioid use disorder
HK40095649A (zh) 具有增强的转导效率并在脑中广泛分布的重组腺相关病毒载体的新型工程化衣壳血清型

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted